🔗 Share this article

As the US undertakes historic adjustments to its immunization guidelines, an unexpected name has emerged in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who rose to prominence by expressing skepticism about coronavirus vaccines throughout the pandemic and has concentrated on potential fatalities after Covid vaccination in her recent time at the FDA.

Scheduled Shifts to Pediatric Immunization Program

Health officials had intended to announce major revisions to the pediatric vaccine schedule earlier this month, bringing the US with Denmark’s vaccine program, sources say – a substantial departure that would put the US at odds with much of the global community with little proof for improved outcomes. This reveal has been postponed until the next year.

In place of Vinay Prasad, Dr. Høeg is set to present at the event. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the center this calendar year.

A Shift at the FDA

This interim role could signify a closer partnership between the pharmaceutical and biologics divisions as Høeg and Dr. Prasad strengthen their influence at the FDA – and it signals a renewed priority upon dismantling already-approved vaccines at the FDA.

Dr. Høeg has frequently advocated for ending specific childhood vaccine recommendations in the US in order to be more in line with Denmark's approach, a society with comprehensive healthcare and a citizenry roughly the population of Wisconsin’s.

In her initial statements, she has continued to focus on vaccines – typically the purview of Prasad, head of the FDA’s CBER – rather than medication approval.

Doubts Over Expertise

The appointee has no obvious background in medication creation, approval processes or leadership, which has been standard for former heads of the CBER. She has worked at the FDA as a senior adviser to the agency head and CBER since March.

“It seems she lacks to have any of the qualifications” for running the CDER, said Dr. Jonathan Howard. “She lacks experience running a scientific study. She lacks experience in running a large organization. She is not an expert in pharmaceutical oversight.”

Past heads of CBER would “be deeply familiar with laws and regulations and the research of drug development”, commented Janet Woodcock. “Clearly, she doesn’t have the sort of resume that prior appointees who ran CBER have had.”

This division has an vast portfolio at the agency, Woodcock emphasized.

“The public just zeroes in on the innovative therapies, but the generic program clears thousands of off-brand pharmaceuticals. There is also a biosimilars division, OTC medication office and other areas, and all of those have to be supervised,” Dr. Woodcock said. “The area you neglect, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a significant management component to the position, which oversees in excess of 5,000 personnel. “It is a huge administrative position, if you do it right,” Woodcock added.

Official Statement and Contentious Initiatives

When asked about inquiries about Høeg’s fitness for the role and whether this appointment signifies more teamwork among agency officials on immunizations, a press secretary responded that the “concerns stem from incorrect presumptions”.

“This background matches the duties of her role,” the spokesperson said, noting the time Dr. Høeg spent counseling the FDA commissioner on “drug safety and regulatory science, including computational safety modeling and shot safety tracking”.

In her interim role, Dr. Høeg takes over the commissioner’s controversial expedited review system, a contentious one-day drug-approval program that apparently troubled her former heads. “How are these therapies being chosen for this fast-track system? Who takes the calls?” Howard said. “There’s a lot of secrecy happening at the FDA right now.”

Broadly speaking, he said, “the Food and Drug Administration seems to be moving towards laxer regulations of most medications, aside from immunizations.”

Public Past Work on Immunizations

Concerning vaccines, Høeg has a more established, if troubling, history, Howard said. She published a research paper using non-validated public submissions to estimate the rate of myocarditis after COVID-19 immunization. She advised the Florida chief medical officer Dr. Joseph Ladapo, who was said to have changed statistics to imply COVID-19 vaccinations are riskier than they are.

Among her “policy goals” for the new federal leadership included altering regulations for novel immunizations and discontinuing “unnecessary” immunizations, she remarked following the vote on a podcast. At the FDA, Dr. Høeg has allegedly proposed preventing adolescent males from receiving COVID-19 vaccinations.

“She is an complete dogmatist who commences with her beliefs and works backwards to fit the data in a very misleading, fraudulent way,” Howard said.

Gaining Influence and a “Push for Payback”

Dr. Høeg joined other dissenters, {like|